Search

Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio

EMPRISE-interim-analysis

Interim analysis from EMPRISE real-world study shows decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists

emperor-preserved-heart-failure-toplineresults

Positive, top-line results announced from the EMPEROR-Preserved Phase III trial in adults with heart failure with preserved ejection fraction

Our Vision

At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases, specifically those affecting the back of the eye.

emperor-reduced-chmp-positive-opinion

CHMP issues positive opinion for the treatment of adults with heart failure with reduced ejection fraction

Imagine: Ecological stoves safeguard family health in Mexico

With Fondo Para la Paz, we’ve developed ecological stoves for safer indoor cooking, enhancing respiratory health for rural Mexican families

preserved-heart-failure-treatment-FDA-US-approval

US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction

SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award

SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award

GPP

Dan

People with Type 2 diabetes (T2D) have an increased risk of heart disease

Patient Documentary

People with type 2 diabetes are two to four times more likely to develop heart disease compared with people without diabetes

Phase II trial results in people living with obesity or overweight

Phase II trial with BI 456906 met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim’s cardio-renal-metabolic focus areas

InSensitive Content: the impact on dermatologists

Learn about the importance of the dermatology community sharing content related to generalized pustular psoriasis on social media.

Shared science for the best cat diabetes management

Diabetes mellitus is a common endocrine disease with increasing prevalence in dogs and cats. Learn how science's made management easier.

EMPRISE-Study

World Rabies Day: BI fights rabies misconceptions

Boehringer Ingelheim joins efforts to fight rabies under this year’s theme for World Rabies Day to raise awareness of the disease and its prevention.

Immunology

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in immunology.

It is about saving lives Alexis Jaliquias feline blood bank

Veterinarian Alexis Jaliquias founded one of the first blood banks for cats in South America

Retinal Health Research

Our research is targeting key mechanisms in the pathogenesis of retinal diseases – vascular dysfunction, neuronal dysfunction and neuronal inflammation.

Two new claims for Nexgard range in EU and Australia

Boehringer Ingelheim expands the label claims of its NexGard® brands for the treatment of two severe skin diseases in dogs in the EU and in Australia.

Our mission in cardiovascular, renal, and metabolic care

Interconnected cardiovascular, renal, and metabolic diseases affect over 1 billion lives globally

Survodutide US FDA Breakthrough Therapy phase 3 trials MASH

Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide

About cardio-renal-metabolic conditions

This page provides an overview of cardiovascular, renal, and metabolic conditions

Heart Failure

Avian influenza prevention at the source

Teshome Mebatsion, Head of Viral Diseases Research at Boehringer Ingelheim, talks about the avian influenza virus, ways of prevention and scenarios for the future.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers